Gabapentin Not Working for Neuropathy? Here Are Your Alternatives

What the published evidence shows about gabapentin's real-world performance and what to consider next.

If you have been on gabapentin for peripheral neuropathy and find yourself wondering whether this is as good as it gets (climbing dose schedules, fighting through brain fog, and still waking up at night with burning feet), you are part of a much larger pattern than most patients realize.

Gabapentin (Neurontin) has been a default first-line agent for painful peripheral neuropathy for nearly two decades, but the systematic evidence reveals a meaningful gap between perception and reality. In the most rigorous meta-analysis of neuropathic pain pharmacotherapy ever conducted (the 2015 Finnerup et al. Lancet Neurology review of 229 placebo-controlled trials), gabapentin requires a Number Needed to Treat (NNT) of 7.2 to produce a 50% pain reduction in a single patient with neuropathic pain.¹ In plain English: only about one in seven patients sees clinically meaningful pain relief from gabapentin alone.

Why Gabapentin Often Falls Short

Gabapentin is a structural analogue of GABA, but it does not act on GABA receptors directly. Its analgesic effect comes from binding to the α2δ subunit of voltage-gated calcium channels, predominantly in the central nervous system, dampening release of excitatory neurotransmitters in the spinal cord.² That mechanism turns down the volume on pain signals as they reach the brain.

It does not, however, address the peripheral nerve damage producing those signals. Gabapentin treats how the brain perceives pain, not the underlying neuropathy. The American Diabetes Association's 2017 position statement on diabetic neuropathy was explicit on this point, noting that available pharmacologic options "partially reduce neuropathic pain" but "do not modify the underlying pathology"³, a candid concession that even the best available agents are not disease-modifying.

This is why patients on stable gabapentin doses commonly drift back toward symptomatic baseline. The peripheral pathology has continued in the background while the central filter does its limited work.

The Hidden Toll: Side Effects That Are Easy to Normalize

Beyond efficacy, gabapentin's side effect profile is often underappreciated. Common adverse effects from clinical trials and post-marketing surveillance⁴ include:

• Cognitive dysfunction. Brain fog, slowed processing speed, and memory complaints (all dose-dependent). For working-age patients, this can compromise job performance; for older adults, it can mimic early dementia.
• Sedation and dizziness. Persistent drowsiness and unsteadiness raise fall risk substantially in older adults, the population most likely to have neuropathy in the first place.
• Weight gain. A frequent and under-discussed effect that can worsen metabolic conditions like Type 2 diabetes, itself a leading cause of the neuropathy gabapentin is prescribed for.
• Mood changes. Depression and, in some cases, suicidal ideation are recognized risks documented on the FDA label.
• Dependency and withdrawal. Abrupt discontinuation can cause significant withdrawal symptoms; structured taper under medical supervision is required.

What the Evidence Says About the Alternatives

Pregabalin (Lyrica), gabapentin's refined successor, is often called the "gold standard." In the foundational randomized placebo-controlled trial published in the Journal of Pain (Richter et al., 2005), only 39% of treated patients achieved a 50% pain reduction, and 38% experienced complications significant enough to be reported as adverse events.⁵ The "gold standard" helps roughly four in ten patients, with a side effect rate that nearly matches the response rate.

Berger and colleagues (2004) characterized real-world prescribing patterns in patients with painful neuropathic disorders: 53.9% on opioids, 39.7% on anti-inflammatory drugs, 21.1% on SSRIs, 11.3% on tricyclics, and 11.1% on anticonvulsants such as gabapentin or pregabalin.⁶ The implication is unflattering. Patients are layered with drug after drug because no single agent reliably resolves the pain, and none of them touch the underlying nerve damage.

A Restorative Alternative: Combined Electrochemical Therapy

At New Promise Neuropathy, the protocol we use is structurally different from medication. Combined Electrochemical Therapy (CET) is a non-surgical, non-opioid, FDA-cleared treatment that pairs precisely calibrated electronic signal stimulation with targeted local anesthetic injections that vasodilate and chemically rest the affected peripheral nerves. The combination is designed to address the nerve damage producing the symptoms, not the brain's perception of those symptoms.

In the most cited open-label trial of this protocol (Cernak et al., Practical Pain Management, 2012), 101 patients with diabetic peripheral neuropathy completed treatment. Average pre-treatment pain scores were 5.39 of 10. Post-treatment scores averaged 0.98, an 81.8% reduction in pain, with consistent improvements in sleep, balance, and walking tolerance.⁷ For the subgroup whose primary symptom was pain rather than numbness (n=70), the reduction reached 87.2%.

Subsequent retrospective follow-up has shown more than 51% of patients maintain their improvement long-term, with documented changes in epidermal nerve fiber density that suggest underlying nerve regeneration rather than transient analgesia.⁸

Other Pharmacologic Alternatives Worth Discussing

If you and your prescribing physician decide medication is the right path, gabapentin is not your only option. Worth discussing:

• Pregabalin (Lyrica). Closely related to gabapentin but with more predictable absorption.
• Duloxetine (Cymbalta). An SNRI with FDA approval for diabetic peripheral neuropathy pain; mechanism distinct from gabapentin.
• Tricyclic antidepressants. Nortriptyline, amitriptyline; moderate evidence in neuropathic pain but often poorly tolerated in older adults.
• Topical capsaicin or lidocaine. Localized relief for focal pain without systemic side effects.

All share gabapentin's foundational limitation: they suppress symptoms without modifying the underlying disease.

The Right Question to Ask Your Provider

Most neuropathy conversations in primary care default to medication adjustment. The more useful question for patients not progressing on pharmacologic management is structurally different: "What are we doing to actually improve my nerve health, not just lower how loudly my brain hears the pain?"

That reframes the goal from suppression to restoration, and opens the door to the conversation we have with every patient who walks into a New Promise Neuropathy clinic.

Frequently Asked Questions

Q: Is it safe to stop taking gabapentin on my own? No. Gabapentin requires a structured taper under your prescribing physician's supervision. Abrupt discontinuation can cause severe rebound pain, anxiety, and in rare cases seizures.

Q: How quickly can I expect to see results from CET? Many patients notice changes within the first several sessions, often improvements in sleep or initial returns of sensation in numb areas. Substantive recovery accumulates over the full 6 to 8 month treatment course.

Q: Can I do CET while still taking gabapentin? Yes. Many patients begin CET while still on gabapentin. As nerve function improves, most coordinate with their prescribing physician to taper or discontinue.

Q: Is CET covered by Medicare or insurance? We accept most major insurance plans including Medicare. Our team verifies your specific coverage before treatment begins.

Take the Next Step

If gabapentin has stopped working, the next step isn't a higher dose. It's a treatment plan that addresses the nerve damage producing your symptoms.

New Promise Neuropathy operates clinics in Arlington, Frisco, Fort Worth, Denton, Las Colinas, Tyler, Weatherford, Sherman, Colleyville, Burleson, and our newest location in Spring, TX, with Missouri City, TX coming soon. Schedule your appointment today.